Research programme: Core-2 GlcNAc-T inhibitors - Inflazyme

Drug Profile

Research programme: Core-2 GlcNAc-T inhibitors - Inflazyme

Alternative Names: Core-2 GlcNAc-T inhibitors research programme - Inflazyme; Core-2 transferase inhibitors research programme - Inflazyme; IPL27 series research programme - Inflazyme; Research programme: Core-2 transferase inhibitors - Inflazyme; Research programme: IPL27 series - Inflazyme

Latest Information Update: 16 Jul 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Core 2 GlcNAc transferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer; Cardiovascular disorders; Diabetes mellitus; Inflammation

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Canada (PO)
  • 17 Jun 2003 GLYCODesign has been acquired by Inflazyme Pharmaceuticals
  • 05 Feb 2003 GLYCODesign has regained all rights to Core-2 inhibitors
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top